Geode Capital Management, LLC Nektar Therapeutics Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,053,085 shares of NKTR stock, worth $2.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,053,085

Previous 2,039,614 0.66%

Holding current value

$2.55 Million

Previous $1.14 Million 67.16%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.49 - $0.96 $6,600 - $12,932	13,471 Added 0.66%	2,053,085 $1.91 Million
Q4 2023 Feb 13, 2024	BUY	$0.42 - $0.57 $35,388 - $48,027	84,258 Added 4.31%	2,039,614 $1.14 Million
Q3 2023 Nov 13, 2023	BUY	$0.51 - $1.05 $30,284 - $62,351	59,382 Added 3.13%	1,955,356 $1.17 Million
Q2 2023 Aug 11, 2023	SELL	$0.53 - $1.03 $859,714 - $1.67 Million	-1,622,102 Reduced 46.11%	1,895,974 $1.1 Million
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $47,593 - $234,249	74,365 Added 2.16%	3,518,076 $2.46 Million

Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $238,973 - $503,845	117,721 Added 3.54%	3,443,711 $7.78 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $218,962 - $370,218	72,027 Added 2.21%	3,325,990 $10.6 Million
Q2 2022 Aug 12, 2022	BUY	$3.17 - $6.17 $2.54 Million - $4.94 Million	800,499 Added 32.63%	3,253,963 $12.4 Million
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $398,573 - $1.31 Million	95,811 Added 4.06%	2,453,464 $13.2 Million
Q4 2021 Feb 11, 2022	SELL	$10.83 - $18.41 $34,287 - $58,286	-3,166 Reduced 0.13%	2,357,653 $31.9 Million
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $370,024 - $533,379	-28,311 Reduced 1.18%	2,360,819 $42.4 Million
Q2 2021 Aug 13, 2021	BUY	$16.52 - $20.4 $1.03 Million - $1.27 Million	62,401 Added 2.68%	2,389,130 $41 Million
Q1 2021 May 12, 2021	BUY	$16.56 - $25.46 $678,181 - $1.04 Million	40,953 Added 1.79%	2,326,729 $46.5 Million
Q4 2020 Feb 12, 2021	BUY	$15.77 - $19.03 $3.18 Million - $3.83 Million	201,442 Added 9.66%	2,285,776 $38.9 Million
Q3 2020 Nov 13, 2020	SELL	$16.59 - $24.79 $1.22 Million - $1.83 Million	-73,798 Reduced 3.42%	2,084,334 $34.6 Million
Q2 2020 Aug 13, 2020	BUY	$16.86 - $23.44 $791,745 - $1.1 Million	46,960 Added 2.22%	2,158,132 $50 Million
Q1 2020 May 14, 2020	BUY	$14.47 - $27.96 $1.03 Million - $2 Million	71,526 Added 3.51%	2,111,172 $37.7 Million
Q4 2019 Feb 13, 2020	SELL	$15.87 - $23.12 $12.3 Million - $17.9 Million	-775,226 Reduced 27.54%	2,039,646 $44 Million
Q3 2019 Nov 12, 2019	BUY	$16.91 - $36.27 $1.58 Million - $3.39 Million	93,359 Added 3.43%	2,814,872 $51.2 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $10 Million - $11.7 Million	323,432 Added 13.49%	2,721,513 $96.7 Million
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $5.18 Million - $7.6 Million	163,885 Added 7.34%	2,398,081 $80.4 Million
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $156,957 - $292,200	5,158 Added 0.23%	2,234,196 $73.3 Million
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $13.1 Million - $19.3 Million	281,776 Added 14.47%	2,229,038 $136 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $4.4 Million - $9.93 Million	-95,097 Reduced 4.66%	1,947,262 $94.9 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $34.2 Million - $64.7 Million	596,388 Added 41.24%	2,042,359 $217 Million
Q4 2017 Feb 13, 2018	BUY	$23.02 - $60.5 $321,313 - $844,459	13,958 Added 0.97%	1,445,971 $86.4 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $918,960 - $1.24 Million	51,656 Added 3.74%	1,432,013 $34.4 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,380,357	1,380,357 $27 Million

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Nektar Therapeutics Transaction History